Pilot study of chemopreventive effect of pioglitazone for colorectal cancer using aberrant crypt foci as a biomarker
- Conditions
- Subjects with aberrant crypt foci (ACF)
- Registration Number
- JPRN-UMIN000001265
- Lead Sponsor
- Gastroenterology Division, Yokohama City University Graduate School of Medicine
- Brief Summary
After administration of pioglitazone, the reduction in the number of ACF was observed.(The Joint Meeting of the 3rd ISC International Conference on Cancer Therapeutics and the 11th International Symposium on Cancer Chemotherapy, Tokyo, Japan, December 2006)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Not provided
a. Liver cirrhosis or chronic hepatic, chronic renal failure b. Women who are pregnant or with a possibility of pregnancy c. Alcohol dependence or drug dependence d. Drug allergy e. Heart failure f. Those who have started to use different medication for diabetes mellitus from pioglitazone-alone (including insulin) in study period g. The patient that it is already taken pioglitazone h. History of cancer i. Family history of colorectal cancer j. The patient currently taking NSAIDs k. Inadequate to entry to this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Observation of ACF using magnifying endoscopy
- Secondary Outcome Measures
Name Time Method